Journal article
Prevalence of Scabies and Impetigo 3 Years After Mass Drug Administration With Ivermectin and Azithromycin
Michael Marks, Lucia Romani, Oliver Sokana, Lazarus Neko, Relmah Harrington, Titus Nasi, Handan Wand, Margot J Whitfeld, Daniel Engelman, Anthony W Solomon, John M Kaldor, Andrew C Steer
Clinical Infectious Diseases | OXFORD UNIV PRESS INC | Published : 2020
DOI: 10.1093/cid/ciz444
Abstract
BACKGROUND: Ivermectin-based mass drug administration has emerged as a promising strategy for the control of scabies and impetigo in settings where the diseases are endemic. Current follow-up data are limited to 12 months for the majority of studies. Longer-term data are vital to inform the sustainability of interventions. METHODS: We conducted a prevalence survey for scabies and impetigo in 10 villages in Choiseul Province of the Solomon Islands 36 months after a single round of ivermectin and azithromycin mass drug coadministration. In the primary analysis, we compared the prevalence of scabies and impetigo at 36 months to the prevalence at baseline. RESULTS: At 36 months, the prevalence o..
View full abstractGrants
Funding Acknowledgements
The study was funded by the International Trachoma Initiative; the Murdoch Children's Research Institute, Australia; the Scobie and Claire Mackinnon Trust, Australia; and the Wellcome Trust. Ivermectin was provided at a reduced cost by Merck Sharp & Dohme Australia.